Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
09:06am, Tuesday, 01'st Jul 2025
Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.
Alnylam Pharmaceuticals Names Garg R&D Chief
12:04pm, Wednesday, 18'th Jun 2025
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
10:05am, Wednesday, 18'th Jun 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
10:11am, Tuesday, 10'th Jun 2025
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
08:00am, Wednesday, 28'th May 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S
3 High-Flying Stocks That Could Soar Even More
06:40am, Saturday, 24'th May 2025
Many investors love the "big mo." That's short for "big momentum.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
10:00am, Monday, 05'th May 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
11:55am, Friday, 02'nd May 2025
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
01:11pm, Thursday, 01'st May 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenst
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
11:35am, Thursday, 01'st May 2025
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
10:20am, Thursday, 01'st May 2025
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago.
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:21am, Tuesday, 29'th Apr 2025
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo
